Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations
Name
520_2016_Article_3152.pdf
Size
411.73 KB
Format
Adobe PDF
Checksum (MD5)
77cfc9b725ba24457003cd90d12c2a80
Author(s) • • • • • • • • •
Elad, Sharon
Barasch, Andrei
Genot, Marie-Thérèse
Lansaat, Liset
van der Brink, Ron
Arnabat-Dominguez, Josep
van der Molen, Lisette
Jacobi, Irene
van Diessen, Judi
de Lange, Jan
Date Issued
March 2016
Journal
Supportive Care in Cancer
Publisher
Springer-Verlag
Citation
Zecha, Judith A. E. M., Judith E. Raber-Durlacher, Raj G. Nair, Joel B. Epstein, Stephen T. Sonis, Sharon Elad, Michael R. Hamblin, et al. “Low Level Laser Therapy/photobiomodulation in the Management of Side Effects of Chemoradiation Therapy in Head and Neck Cancer: Part 1: Mechanisms of Action, Dosimetric, and Safety Considerations.” Supportive Care in Cancer, vol. 24, no. 6, March 2016, pp. 2781–2792.
Version
Author's final manuscript
Abstract
Purpose:
There is a large body of evidence supporting the efficacy of low level laser therapy (LLLT), more recently termed photobiomodulation (PBM), for the management of oral mucositis (OM) in patients undergoing radiotherapy for head and neck cancer (HNC). Recent advances in PBM technology, together with a better understanding of mechanisms involved, may expand the applications for PBM in the management of other complications associated with HNC treatment. This article (part 1) describes PBM mechanisms of action, dosimetry, and safety aspects and, in doing so, provides a basis for a companion paper (part 2) which describes the potential breadth of potential applications of PBM in the management of side-effects of (chemo)radiation therapy in patients being treated for HNC and proposes PBM parameters.
Methods:
This study is a narrative non-systematic review.
Results:
We review PBM mechanisms of action and dosimetric considerations. Virtually, all conditions modulated by PBM (e.g., ulceration, inflammation, lymphedema, pain, fibrosis, neurological and muscular injury) are thought to be involved in the pathogenesis of (chemo)radiation therapy-induced complications in patients treated for HNC. The impact of PBM on tumor behavior and tumor response to treatment has been insufficiently studied. In vitro studies assessing the effect of PBM on tumor cells report conflicting results, perhaps attributable to inconsistencies of PBM power and dose. Nonetheless, the biological bases for the broad clinical activities ascribed to PBM have also been noted to be similar to those activities and pathways associated with negative tumor behaviors and impeded response to treatment. While there are no anecdotal descriptions of poor tumor outcomes in patients treated with PBM, confirming its neutrality with respect to cancer responsiveness is a critical priority.
Conclusion:
Based on its therapeutic effects, PBM may have utility in a broad range of oral, oropharyngeal, facial, and neck complications of HNC treatment. Although evidence suggests that PBM using LLLT is safe in HNC patients, more research is imperative and vigilance remains warranted to detect any potential adverse effects of PBM on cancer treatment outcomes and survival.
MIT Department
Institute for Medical Engineering and Science
Harvard University--MIT Division of Health Sciences and Technology
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1007/s00520-016-3152-z